Purchase this article with an account.
Neringa Jurkute, Priya D. Shanmugarajah, Marios Hadjivassiliou, Jenny Higgs, Miodrag Vojcic, Iain Horrocks, Yann Nadjar, Valerie Touitou, Guy Lenaers, Roy Poh, James Acheson, Anthony G. Robson, F. Lucy Raymond, Mary M. Reilly, Patrick Yu-Wai-Man, Anthony T. Moore, Andrew R. Webster, Gavin Arno, for the Genomics England Research Consortium; Expanding the FDXR-Associated Disease Phenotype: Retinal Dystrophy Is a Recurrent Ocular Feature. Invest. Ophthalmol. Vis. Sci. 2021;62(6):2. doi: https://doi.org/10.1167/iovs.62.6.2.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The purpose of this study was to report retinal dystrophy as a novel clinical feature and expand the ocular phenotype in patients harboring biallelic candidate FDXR variants.
Patients carrying biallelic candidate FDXR variants were identified by whole genome sequencing (WGS) as part of the National Institute for Health Research BioResource rare-disease and the UK's 100,000 Genomes Project (100KGP) with an additional case identified by exome sequencing. Retrospective clinical data were collected from the medical records. Haplotype reconstruction was performed in families harboring the same missense variant.
Ten individuals from 8 unrelated families with biallelic candidate variants in FDXR were identified. In addition to bilateral optic atrophy and variable extra-ocular findings, 7 of 10 individuals manifested retinal dystrophy comprising dysfunction and degeneration of both rod and cone photoreceptors. Five of 10 subjects had sensorineural hearing loss. The previously unreported missense variant (c.1115C > A, p.(Pro372His)) was found in 5 of 8 (62.5%) study families. Haplotype reconstruction using WGS data demonstrated a likely ancestral haplotype.
FDXR-associated disease is a phenotypically heterogeneous disorder with retinal dystrophy being a major clinical feature observed in this cohort. In addition, we hypothesize that a number of factors are likely to drive the pathogenesis of optic atrophy, retinal degeneration, and perhaps the associated systemic manifestations.
This PDF is available to Subscribers Only